Conference
VRG Presenting at Re:Biotech Hungary

We were proud to represent all VRG ventures at this year's Re:Biotech Hungary conference organized by the Magyar Biotechnológiai Szövetség / Hungarian Biotech Association. It was an outstanding opportunity to network with prominent players of the Hungarian Biotech community.

Our friends and colleagues presented exciting breakthroughs and advancements:

VRG Tx - Miniprotein platform: Lead asset Kv1.3 inhibitor advancing through preclinical development and targeting IND in Q4 2026. Using our AI-MPRO platform, we validated first de novo–designed IL-11–targeting miniproteins within six months - led by Gábor Oroszlán, Ph.D.

‍Novamigra Tx: Preparations for first-in-human trial ongoing: secured ~3M EUR commitments for ~10M EUR fundraising round, started CMC development, and completed regulatory consulting with FDA & Hungarian NNGYK - led by Tamás Kökény‍

CREATe Tx: Based on data from a human-relevant model of focal epilepsy, seizures may be completely prevented with our technology - led by Tamás Kitka

‍We are looking forward to participating many similar events as the Hungarian Biotech Association is on the re:rise lead by Zita Sepsi and Benjamin Kiss!

Latest
News
The latest industry news, interviews, technologies, and resources.
View All News
Latest
News
The latest industry news, interviews, technologies, and resources.
Kv1.3
May 12, 2026
By VRG Therapeutics
Press Release
Kv1.3
April 13, 2026
By VRG Therapeutics
VRG Miniprotein Secures €4M Catalyst Grant to Advance Kv1.3 Program
View All News